Dieatary Supplementation with BioBran-MGN-3 Increases Innate Resistance and Reduces the Incidence of Influenza-like Illnesses s in Elderly Subjects: A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial PEER REVIEWED

  • Ahmed F. Elsaid , Sudhanshu Agrawal , Anshu Agrawal and Mamdooh Ghoneum
  • (edited by Chris Gutch PhD.)
  • 2021

Abstract: Influenza-like illness (ILI) remains a major cause of severe mortality and morbidity in the elderly. Aging is associated with a decreased ability to sense pathogens and mount effective innate and adaptive immune responses, thus mandating the development of protective nutraceuticals. Biobran/MGN-3, an arabinoxylan from rice bran, has potent anti-aging and immunomodulatory effects, suggesting that it may be effective against ILI. The objective of the current study was to investigate the effect of Biobran/MGN-3 on ILI incidence, natural killer (NK) cell activity, and the expressions of RIG-1 (retinoic acid-inducible gene 1), MDA5 (melanoma differentiation-associated protein 5), and their downstream signaling genes ISG-15 (interferon-stimulated genes 15) and MX1 (myxovirus (influenza) resistance 1, interferon-inducible). A double-blind, placebo-controlled clinical trial included eighty healthy older adults over 55 years old, 40 males and 40 females, who received either a placebo or Biobran/MGN-3 (500 mg/day) for 3 months during known ILI seasonality (peak incidence) in Egypt. The incidence of ILI was confirmed clinically according to the WHO case definition criteria. Hematological, hepatic, and renal parameters were assessed in all subjects, while the activity of NK and NKT (natural killer T) cells was assessed in six randomly chosen subjects in each group by the degranulation assay. The effect of Biobran/MGN-3 on RIG-1 and MDA5, as well as downstream ISG15 and MX1, was assessed in BEAS-2B pulmonary epithelial cells using flow cytometry. The incidence rate and incidence density of ILI in the Biobran/MGN-3 group were 5.0% and 0.57 cases per 1000 person-days, respectively, compared to 22.5% and 2.95 cases per 1000 person-days in the placebo group. Furthermore, Biobran/MGN-3 ingestion significantly enhanced NK activity compared to the basal levels and to the placebo group. In addition, Biobran/MGN-3 significantly upregulated the expression levels of RIG-1, MDA5, ISG15, and MX1 in the human pulmonary epithelial BEAS-2B cell lines. No side effects were observed. Taken together, Biobran/MGN-3 supplementation enhanced the innate immune response of elderly subjects by upregulating the NK activity associated with reduction of ILI incidence. It also upregulated the intracellular RIG-1, MDA5, ISG15, and MX1 expression in pulmonary epithelial tissue cultures. Biobran/MGN-3 could be a novel agent with prophylactic effects against a wide spectrum of respiratory viral infections that warrants further investigation.

We use cookies to improve your experience on our website. For more details see our cookie policy.

Like many other websites, we use cookies to provide enhanced functionality and track the usage of our websites with Google Analytics, and some of our third-party advertisers might use them to deliver adverts tailored to what they think you might be interested in.

What are cookies?

Cookies are small text files which can be sent to browser when you visit websites and saved to your device (computer or other device with Internet access, i.e. smartphone or tablet). Cookies are saved in the folder for files of your browser. Cookies usually contain the name of the website they come from and the date of origin. Upon your next visit the browser loads cookies again and sends these information back to the website which originally created cookies. Cookies we use do not harm your computer.

Using cookies

By using this website you give your consent to using cookies in compliance with your browser settings. If you visit our websites, acceptance of cookies is allowed in your browser, you do not change your browser settings and continue visiting our websites we consider it as accepting our conditions for using cookies.

Why are we using cookies?

Cookies are used to optimally create and constantly improve the quality of our services, adjust them to your interests and needs and improve their structure and contents. We do not use data obtained by using cookies to contact users by mail, e-mail or telephone.

How to change settings of cookies?

Majority of browsers have been originally set to automatically accept cookies. This settings can be changed by blocking cookies or by a notification in case cookies are to be sent to your device. Instructions for changing cookies are available in the option “Help” of every browser. If you use different devices to access websites (e.g. computer, smartphone, tablet), we recommend you to adjust every browser on each of them to your preferences regarding cookies.

Why to keep settings of cookies?

Using cookies and permitting cookies in your browser is your decision. However, in case you change settings of cookies, functionality of some of our websites can be limited and their user comfort reduced.